VANCOUVER, BC, March 16, 2023 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) today announced that it has acquired TAETSoftware Corp (“TAETCo”), a Vancouver-based clinical studies management company engaged in the development and commercialization of the Trial Adverse Events Tracker (“TAET”) technology platform, a proprietary software application which will enable […]
Author Archives: Biovaxys
VANCOUVER, BC, December 16th, 2022 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that possibly based on the selected study design, results from The Ohio State University (“Ohio State”) animal study, its collaborator on the development of BioVaxys’ pan-sarbecovirus vaccine, did not demonstrate that immunization of study animals with BVX-1021, followed […]
VANCOUVER, BC, December 1st, 2022 — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) is pleased to announce the successful sterile and bacteria-free test-run production of BVX-0918, the Company’s bi-haptenized autologous ovarian cancer vaccine. The complete manufacturing of BVX-0918 from a cancer patient’s ovarian tumor now validates the production protocols that had been in […]
Vancouver, British Columbia, November 28, 2022, BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it has closed the first tranche (“Tranche 1”) of a non-brokered private placement (the “Private Placement”). Pursuant to Tranche 1 of the Private Placement, the Company has issued 940,000 units (“Units”) at a price […]
Vancouver, British Columbia, November 9, 2022, BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it has completed a non-brokered private placement (the “Private Placement”) consisting of 4,050,000 units (“Units”) at a price of $0.10 per Unit for total gross proceeds of $405,000. Each Unit consists of one common […]
Vancouver, British Columbia, October 27, 2022 – BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) announces that it has agreed to settle an aggregate of $150,000 in debt with one vendor through the issuance of common shares to be issued at a deemed price of $0.20 per common share (the […]
VANCOUVER, British Columbia, Oct. 14, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC-QB: BVAXF) (“BioVaxys” or the “Company”) announces that, further to its news release dated October 6, 2022, it has settled an aggregate of $300,000 in debt through the issuance of common shares issued at a deemed price of $0.15 per common […]
Agreement Includes Right of First Refusal in the US for Ovosicare and Libicare VANCOUVER, BC, October 6th, 2022 /CNW/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that it has executed a binding Term Sheet (“Term Sheet” or “Agreement”) with Procare Health Iberia, S.L. (“Procare Health”), of Barcelona, Spain (“Procare Health”), for […]
VANCOUVER, BC, September 28th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” or “Company”) announced today that in an action that further expands the value of their IP portfolio, the Company has broadened the patent coverage for its viral vaccine platform by filing an international patent application through the Patent Cooperation Treaty (“PCT”) […]
VANCOUVER, BC , August 8th, 2022 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, OTCQB: BVAXF) (“BioVaxys” or the “Company”) is pleased to announce that Mr. Craig Loverock has joined the Company as Chief Financial Officer. Mr. Loverock is replacing Mr. Lachlan McLeod, who has been the acting CFO following the transition from Lions Bay Mining Inc. to BioVaxys in […]